 |
|
. . . But Aspirin May Not Help
Mike Mitka
JAMA. 2002;287:2067.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Some people who take aspirin to protect against heart disease are resistant to the medication's benefits. These people have a higher risk of dying from heart disease, said researchers in a study reported in a March 25 rapid-access publication of Circulation.
In the study, researchers at the University of Western Australia, Royal Perth Hospital, found that patients taking aspirin who had a high level of thromboxane in their urine had a 3.5 times higher risk of cardiovascular death than patients who had the lowest level.
The researchers said it appeared that aspirin did not effectively block thromboxane synthesis in some people, making them resistant to the protective effects of the drug. They said their findings raise the possibility that elevated urinary thromboxane levels might identify patients who are relatively resistant to aspirin and who may benefit from additional antiplatelet therapies or treatments that more effectively block in vivo . . . [Full Text of this Article]
|
